Neurobehavioral Signatures of Sign- and Goal-Tracking in Emerging Adults: Translation of a Preclinical Model
Launched by UNIVERSITY OF MICHIGAN · Jul 22, 2025
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This study is looking at how different people’s brains and behaviors respond to rewards and attention, especially in young adults aged 18 to 20. Researchers want to understand why some people are more driven by immediate cues or signs (called “sign-tracking”) and others focus more on their goals (called “goal-tracking”), and how this relates to attention, impulse control, and the way the brain processes rewards. This could help explain why some people might be more at risk for substance use or other behaviors.
To take part, you need to be between 18 and 20 years old, right-handed, able to give consent, and speak English. People with certain medical or mental health conditions, recent treatments for substance use, or MRI restrictions (like having metal implants or being pregnant) cannot join. If you join, you’ll likely complete some tests that look at your attention, impulses, and how your brain responds to rewards, possibly including brain scans. The study is not yet recruiting, but it aims to learn more about how personality and brain function relate to behavior in young adults.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18-20 years old at baseline
- • Right-handed
- • Medically/physically able to give informed consent
- • English-speaking
- • Substance use is free to vary, but for participants with a history of substance use, ≥ 1 use of cannabis (including less than a full dose)
- Exclusion Criteria:
- • Acute or chronic medical or neurological illness (e.g., diabetes, epilepsy, migraine)
- • History of psychosis in self or first-degree relative
- • Current treatment for substance use disorder
- • Current or past 6-month treatment with centrally acting medications (not including attention deficit hyperactivity disorder (ADHD) medication)
- • Intelligence quotient (IQ) \< 70
- • Lifetime history of head trauma with loss of consciousness \> 5 minutes
- • Colorblindness
- • MRI contraindication (e.g., pregnancy, metal implants, claustrophobia) per protocol
About University Of Michigan
The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Patients applied
Trial Officials
Lora Cope, PhD
Principal Investigator
University of Michigan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported